Prestige Wealth Management Group LLC Purchases 6,405 Shares of Johnson & Johnson $JNJ

Prestige Wealth Management Group LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 23.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 34,029 shares of the company’s stock after acquiring an additional 6,405 shares during the period. Johnson & Johnson accounts for about 1.3% of Prestige Wealth Management Group LLC’s holdings, making the stock its 19th biggest position. Prestige Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $7,042,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. BBR Partners LLC lifted its holdings in shares of Johnson & Johnson by 3.2% in the fourth quarter. BBR Partners LLC now owns 30,596 shares of the company’s stock valued at $6,332,000 after purchasing an additional 949 shares in the last quarter. SlateStone Wealth LLC lifted its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. SlateStone Wealth LLC now owns 69,496 shares of the company’s stock valued at $14,382,000 after purchasing an additional 860 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $64,968,000. Harvest Fund Management Co. Ltd lifted its holdings in shares of Johnson & Johnson by 200.6% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 2,333 shares of the company’s stock valued at $483,000 after purchasing an additional 1,557 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its holdings in shares of Johnson & Johnson by 18.9% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 20,684 shares of the company’s stock valued at $4,281,000 after purchasing an additional 3,288 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $228.32 on Friday. The business’s fifty day simple moving average is $232.12 and its 200 day simple moving average is $225.92. The firm has a market capitalization of $549.63 billion, a P/E ratio of 26.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.26. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson presented multiple favorable ASCO 2026 data readouts, including practice-changing prostate cancer results for apalutamide and encouraging oncology/myeloma updates that support its specialty drug growth narrative. ASCO 2026 Data Underscore Johnson & Johnson’s Expanding Specialty Drug Story
• Positive Sentiment: Nipocalimab showed sustained lupus disease control in Phase 2 JASMINE data, with stronger responses in autoantibody-positive patients, bolstering J&J’s autoimmune pipeline and the case for future commercialization. Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus disease activity in a Phase 2 study
• Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s potential, showing greater clinical response in patients with higher autoantibody and IgG levels, which may indicate a meaningful treatment effect in more severe cases. Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren’s disease
• Neutral Sentiment: Newsweek named Johnson & Johnson among the World’s Greenest Companies 2026, a positive reputation item but not a major immediate earnings driver. Goldman Sachs, Johnson & Johnson, MetLife Named Among Newsweek’s World’s Greenest Companies 2026

Analyst Ratings Changes

A number of research analysts have recently weighed in on JNJ shares. Raymond James Financial raised their target price on Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Guggenheim raised their target price on Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a report on Monday, April 20th. Wells Fargo & Company raised their target price on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Finally, Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday, May 13th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.